-
Peer-reviewed scientific presentation: “Rethinking lung cancer screening: AI/ML longitudinal diagnostics beyond nodule size growth”
-
AI Theater Presentation: “Eyonis® LCS: Transforming Lung Cancer Screening with AI-Driven Early Detection and Diagnosis”
-
The Median iCRO and eyonis® teams will be present at booth #5438, AI Showcase, South Hall, Level 3, McCormick Place
SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory news:
Midstream Technologies (FR0011049824, ALMDT, PEA/PME eligible, “Median” or “The Company”)maker of eyonis®, an artificial intelligence (AI)-based software-as-a-medical-device (SaMD) suite for early cancer diagnosis, and a leading global provider of AI-based image analysis and central imaging services for oncology drug developers, today announced its participation in the 2025 Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, Illinois, USA, McCormick Place, November 30 to December. 4, 2025. The Median iCRO and eyonis® teams will welcome interested parties at Booth #5438, AI Showcase, South Hall, Level 3, from November 30 to December 3 (technical exhibition dates).
The company will share the latest developments in SaMD eyonis® Lung Cancer Screening (LCS), as well as the most recent advancements in iCRO and AI-based core oncology testing imaging services for pharmaceutical companies.
eyonis® LCS was designed to transform lung cancer screening and address two critical clinical challenges: improving diagnostic accuracy and increasing program efficiency. It was evaluated in two pivotal studies required for marketing authorization in the United States and Europe, both of which were successfully completed: REALITY (ClinicalTrials.gov ID: NCT06576232) and REVIVE (ClinicalTrials.gov ID: NCT06751576). Based on this data, Median Technologies submitted its US 510(k) clearance application for eyonis® LCS on May 13, 2025, and its request for European CE marking June 30, 2025. eyonis® LCS is currently under review for FDA 510(k) clearance and CE Marking and is not yet commercially available in the United States or Europe.
“We are excited to share the latest data from eyonis® LCS with the global radiology community at the RSNA 2025 Annual Meeting. eyonis® LCS enables earlier diagnosis, streamlines workflows, promotes program adherence, and ultimately promotes better patient outcomes. Our software as a medical device is poised to play a key role in accelerating the global adoption of life-saving screening programs. In the United States, cancer screening of the lung is already established and procedures that leverage AI for quantitative tissue analysis on low-dose CT scans currently enjoy reimbursement of $650 for each use. Across Europe, national initiatives are gaining momentum to implement similar programs, with Germany being the latest example as it prepares to launch its organized screening program in April 2026. said Thomas Bonnefont, COO and CCO eyonis® at Median Technologies.
The Median Eyonis® team will present at RSNA:
About eyonis® LCS: eyonis® Lung Cancer Screening (LCS) is an artificial intelligence-based computer-aided detection and diagnosis (CADe/CADx) system, or software as a medical device (SaMD) that uses machine learning to help analyze imaging data generated by low-dose computed tomography (LDCT). eyonis® LCS allows radiologists to diagnose lung cancer at its earliest and most treatable stages, when curative options remain possible for many patients. eyonis® LCS has been the subject of two pivotal studies necessary for marketing authorization in the United States and Europe: REALITY (Clinicaltrials.gov ID: NCT06576232) and REVIVE (Clinicaltrials.gov ID: NCT06751576), both of which were successfully completed. Based on this crucial data, Median Technologies submitted a US 510(k) clearance application for eyonis® LCS on May 13, 2025, and a European CE Mark application on June 30, 2025. eyonis® LCS is currently under review for FDA 510(k) clearance and CE marking and is not yet commercially available in the US and Europe.
About the RSNA Annual Meeting: The Radiological Society of North America Annual Meeting is the largest medical imaging conference in the world, offering more than 300 educational courses and more than 2,800 scientific presentations covering all subspecialties. RSNA 2025 expects approximately 50,000 medical imaging professionals, representing more than 120 countries. RSNA hosts the largest medical equipment exhibition, showcasing products and services from nearly 700 manufacturers, suppliers and developers, from innovative startups to industry giants. For more information about the 2025 RSNA Annual Meeting, visit
About Median Technologies: A pioneer in innovative software as medical device and imaging services, Median Technologies leverages cutting-edge AI to improve the accuracy of early cancer diagnosis and treatment. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, a software suite based on AI/ML technology as a medical device (SaMD). Median enables biopharmaceutical entities and clinicians to advance patient care and accelerate the development of new therapies. The French company, present in the United States and China, is listed on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the PME share savings plan (PEA-PME). For more information, visit www.mediantechnologies.com.
Forward-looking statements
This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates and the assumptions on which they are based, statements regarding plans, objectives, intentions and expectations regarding future financial results, events, operations, services, product development and potential or future performance.
These forward-looking statements can often be identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” or “plans” and other similar expressions. Although Median’s management believes such forward-looking statements to be reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, which could cause actual results and events to differ materially from those expressed, implied or projected by the forward-looking information and statements.
All forward-looking statements contained in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update forward-looking information or statements, subject to applicable regulations, in particular articles 223-1 et seq. of the Consumer Code. of the general regulations of the Financial Markets Authority.
Contacts
MEDIAN TECHNOLOGIES
Emmanuelle Leygues
Vice President, Corporate Marketing and Financial Communications
06 10 93 58 88
[email protected]
Investors – SEITOSEI ACTIFIN
Ghislaine Gasparetto
06 85 36 76 81
[email protected]
American media and investors – COHESION OFFICE
Chris Maggos
+41 79 367 6254
[email protected]
Press – ULYSSE COMMUNICATION
Bruno Arabe
06 87 88 47 26
[email protected]
Nicolas Entz
06 33 67 31 54
[email protected]
